IL215789A0 - Anti-cancer drugs, and uses relating for malignant malignant melanoma and other cancers - Google Patents
Anti-cancer drugs, and uses relating for malignant malignant melanoma and other cancersInfo
- Publication number
- IL215789A0 IL215789A0 IL215789A IL21578911A IL215789A0 IL 215789 A0 IL215789 A0 IL 215789A0 IL 215789 A IL215789 A IL 215789A IL 21578911 A IL21578911 A IL 21578911A IL 215789 A0 IL215789 A0 IL 215789A0
- Authority
- IL
- Israel
- Prior art keywords
- malignant
- cancers
- cancer drugs
- uses relating
- melanoma
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 201000001441 melanoma Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D517/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains three hetero rings
- C07D517/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN959CH2009 | 2009-04-27 | ||
| PCT/IN2010/000262 WO2010125575A1 (en) | 2009-04-27 | 2010-04-26 | Anti-cancer drugs, and uses relating for malignant melanoma and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL215789A0 true IL215789A0 (en) | 2012-01-31 |
Family
ID=42992332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL215789A IL215789A0 (en) | 2009-04-27 | 2011-10-23 | Anti-cancer drugs, and uses relating for malignant malignant melanoma and other cancers |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8143237B2 (enExample) |
| EP (1) | EP2424351B1 (enExample) |
| JP (1) | JP5571168B2 (enExample) |
| KR (1) | KR20120006554A (enExample) |
| CN (1) | CN102438449B (enExample) |
| AU (1) | AU2010243213B2 (enExample) |
| BR (1) | BRPI1006651A2 (enExample) |
| CA (1) | CA2759519A1 (enExample) |
| IL (1) | IL215789A0 (enExample) |
| NZ (1) | NZ595602A (enExample) |
| WO (1) | WO2010125575A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9090633B2 (en) | 2010-11-18 | 2015-07-28 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| CN103221048A (zh) | 2010-11-18 | 2013-07-24 | 卡斯纳莱拉创新药物私人有限公司 | 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法 |
| AU2011340063B2 (en) * | 2010-12-09 | 2016-03-24 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| WO2012176212A1 (en) | 2011-06-20 | 2012-12-27 | V.B. Medicare Pvt. Ltd. | Carrier based nanogel formulation for skin targeting. |
| KR101418776B1 (ko) | 2011-09-28 | 2014-07-14 | 사회복지법인 삼성생명공익재단 | 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법 |
| CN103906742A (zh) * | 2011-09-28 | 2014-07-02 | 世宗大学校产学协力团 | 硒吩稠合芳族化合物和其制备方法 |
| WO2014012074A2 (en) | 2012-07-12 | 2014-01-16 | Euclises Pharmaceuticals, Inc. | No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents |
| US9044464B2 (en) | 2012-07-12 | 2015-06-02 | Euclises Pharmaceuticals, Inc. | No-releasing guanidine-coxib anti-cancer agents |
| US9505765B2 (en) | 2012-07-26 | 2016-11-29 | Confluence Life Sciences Inc. | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment |
| US20140199728A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| WO2016118951A2 (en) | 2015-01-23 | 2016-07-28 | Confluence Life Sciences, Inc. | Heterocyclic itk inhibitors for treating inflammation and cancer |
| CN108129475A (zh) * | 2018-02-08 | 2018-06-08 | 中南大学湘雅三医院 | 一种生物光敏剂及其制备方法和应用 |
| KR102648781B1 (ko) | 2021-11-09 | 2024-03-19 | 국립공주대학교 산학협력단 | 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도 |
| WO2025005748A1 (ko) * | 2023-06-29 | 2025-01-02 | (주)아이젠사이언스 | 신규 셀레노펜 유도체 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620804B2 (en) * | 1996-06-03 | 2003-09-16 | Purdue Research Foundation | Selenophene anti-tumor agents |
| DE69724472T2 (de) * | 1996-06-03 | 2004-06-17 | Purdue Research Foundation, West Lafayette | Selenophen-antitumormittel |
| WO2008016664A2 (en) * | 2006-08-02 | 2008-02-07 | University Of Massachusetts Lowell | Compositions and methods for treating cancer with dacarbazine nanoemulsions |
| WO2010029577A2 (en) * | 2008-09-15 | 2010-03-18 | Ganga Raju Gokaraju | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
-
2010
- 2010-04-26 BR BRPI1006651-9A patent/BRPI1006651A2/pt not_active IP Right Cessation
- 2010-04-26 EP EP10769410.1A patent/EP2424351B1/en not_active Not-in-force
- 2010-04-26 CA CA2759519A patent/CA2759519A1/en not_active Abandoned
- 2010-04-26 NZ NZ595602A patent/NZ595602A/xx unknown
- 2010-04-26 JP JP2012506649A patent/JP5571168B2/ja not_active Expired - Fee Related
- 2010-04-26 KR KR1020117027765A patent/KR20120006554A/ko not_active Ceased
- 2010-04-26 AU AU2010243213A patent/AU2010243213B2/en not_active Ceased
- 2010-04-26 CN CN201080016304.7A patent/CN102438449B/zh not_active Expired - Fee Related
- 2010-04-26 WO PCT/IN2010/000262 patent/WO2010125575A1/en not_active Ceased
- 2010-04-26 US US12/767,647 patent/US8143237B2/en not_active Expired - Fee Related
-
2011
- 2011-10-23 IL IL215789A patent/IL215789A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102438449B (zh) | 2014-06-18 |
| EP2424351A1 (en) | 2012-03-07 |
| EP2424351A4 (en) | 2013-04-03 |
| AU2010243213A1 (en) | 2011-10-27 |
| JP2012525329A (ja) | 2012-10-22 |
| US8143237B2 (en) | 2012-03-27 |
| CA2759519A1 (en) | 2010-11-04 |
| AU2010243213B2 (en) | 2014-09-11 |
| JP5571168B2 (ja) | 2014-08-13 |
| NZ595602A (en) | 2013-05-31 |
| US20100272678A1 (en) | 2010-10-28 |
| KR20120006554A (ko) | 2012-01-18 |
| CN102438449A (zh) | 2012-05-02 |
| BRPI1006651A2 (pt) | 2015-08-25 |
| WO2010125575A1 (en) | 2010-11-04 |
| EP2424351B1 (en) | 2015-10-21 |
| HK1166591A1 (en) | 2012-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL215789A0 (en) | Anti-cancer drugs, and uses relating for malignant malignant melanoma and other cancers | |
| IL211366A0 (en) | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | |
| PL3363456T3 (pl) | Nowa immunoterapia względem wielu nowotworów, w tym raka układu trawiennego i raka żołądka | |
| ZA201105791B (en) | New adenosine receptor ligands and uses thereof | |
| IL217208A (en) | History of cryptophycin, critophycin conjugates, processes for their preparation, and their use as anticancer agents | |
| PH12012500574A1 (en) | Notch1-antagonist-resistant cancer(s) using notch3 antagonists | |
| IL209854A0 (en) | Supression of cancers | |
| ZA201405090B (en) | Molecular sieve material,its synthesis and use | |
| IL207958A0 (en) | Allogeneic cancer cell - based immunotherapy | |
| PL2483176T3 (pl) | Wkład z napojem w proszku | |
| EP2520651A4 (en) | SIRNA FOR INHIBITING THE C-MET EXPRESSION AND ANTICREPLAY COMPOSITION THEREWITH | |
| GB0915249D0 (en) | Drug carrier | |
| EP2268146A4 (en) | ANTICANCER AGENTS BASED ON INDOLINE | |
| IL214319A (en) | Chemotherapeutic agent for cancer containing cholesterol derivative and anticancer agent | |
| GB0920896D0 (en) | Improvements in cancer chemotherapy | |
| GB0811599D0 (en) | Improvements in anticancer drugs | |
| GB0809730D0 (en) | Improvements in the chemotherapy of cancer | |
| GB0818566D0 (en) | Improvements in the chemotherapy of cancer | |
| GB0713426D0 (en) | Improvements in anticancer drugs | |
| GB0921254D0 (en) | Topical anti-skin cancer, cosmetic and pharmaceutical compositions and processes for preparing them | |
| GB201004712D0 (en) | Improvements in the chemotherapy of cancer | |
| GB201002199D0 (en) | Improvements in the chemotherapy of cancer | |
| TWM388027U (en) | Notebook lap pad | |
| GB0718208D0 (en) | Improvement in cancer chemotherapy | |
| IL216781A0 (en) | Perindopril tosylate |